A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.
Commentary|Articles|January 22, 2026
Key Patient Takeaways From the 2026 ASCO GI Cancers Symposium
Author(s)Ryan Scott
Fact checked by: Spencer Feldman
Experts highlight key themes from the ASCO GI Cancers Symposium, including the growing role of AI and an increased emphasis on patient-centered decision-making.
Advertisement
Advertisement
During the
Related to this article
In a study of more than 250,000 older adults presented at ASTRO 2026, people with depression who started talk therapy within a week of their cancer diagnosis had a 27% lower risk of dying from their cancer. But most people with depression received no mental health treatment at all.
Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.
Living with incurable small lymphocytic lymphoma means facing new health challenges and fears while finding a balance between caution, optimism and daily life.
Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers should prioritize themselves.
Endoscopic nipple-sparing mastectomy may improve recovery, reduce scarring and support quality of life for people undergoing breast cancer surgery.
Ameluz photodynamic therapy is the first light-based treatment the FDA has approved for a skin cancer. Here's who it's for, how it works and how it compares with surgery.
The FDA has approved Pixclara, the first FET-PET imaging agent for glioma in the U.S. Here's what it does, how accurate it is and why it matters for anyone waiting on an MRI result.
Advertisement
Advertisement